Optum drives UnitedHealth’s better-than-expected earnings

MedCity News - | January 16, 2020

In a year when healthcare costs continued to increase, UnitedHealth Group reported better-than-expected results at the end of 2019. The company reported earnings of $19.68 billion in 2019, up 13 percent year-over-year. UnitedHealth saw improving margins in most of its business segments, with its Optum segment reporting double-digit growth across the board. The company also managed to grow its already large presence in the Medicare Advantage market, despite several new competitors. Overall, UnitedHealth Group’s revenues fell below expectations, at $242.15 billion, though they were still up 7 percent form 2018. As with previous years, the amount it collected in premiums has continued to creep up. In 2019, UnitedHealth Group collected $189.7 billion. The prior year, it collected $178.1 billion.

Spotlight

Catalysis is an essential part of many pharmaceutical processes. With increasing innovation in catalytic chemistry coupled with ever increasing regulatory requirements for residual levels of metal catalysts, particularly Platinum and Palladium, the removal of metal from the product in a simple and pure manner is crucial. In addition, the manufacturing of more potent APIs means containment is often critical. As regulatory agencies continue to press for more stringent requirements for the purity of pharmaceutical products, metal scavengers play an increasing role in achieving the level of purity required. Scavenging Technologies is a solution provider to the pharmaceutical industry with meaningful innovation and many years of experience providing individual support and engineered options.

Spotlight

Catalysis is an essential part of many pharmaceutical processes. With increasing innovation in catalytic chemistry coupled with ever increasing regulatory requirements for residual levels of metal catalysts, particularly Platinum and Palladium, the removal of metal from the product in a simple and pure manner is crucial. In addition, the manufacturing of more potent APIs means containment is often critical. As regulatory agencies continue to press for more stringent requirements for the purity of pharmaceutical products, metal scavengers play an increasing role in achieving the level of purity required. Scavenging Technologies is a solution provider to the pharmaceutical industry with meaningful innovation and many years of experience providing individual support and engineered options.

Related News

PHARMACY MARKET

Thermo Fisher Scientific and AstraZeneca to Co-Develop NGS-based Companion Diagnostics

Thermo Fisher Scientific | September 03, 2021

Thermo Fisher Scientific's clinical sequencing business and AstraZeneca today announced they will co-develop next-generation sequencing (NGS)-based companion diagnostics (CDx) to support AstraZeneca's expanding portfolio of targeted therapies. The companies will collaborate under a multiyear, global agreement. "As the pipeline of targeted therapies expands, the availability of diagnostic tools that can interrogate multiple biomarkers simultaneously will ensure patients can be matched with the right therapies more rapidly – this is the promise of precision medicine," said Garret Hampton, president of clinical next-generation sequencing and oncology at Thermo Fisher Scientific. "Introduction of diagnostic tools early in the process of drug development can further facilitate the success of companion diagnostic development – and that's what we're doing with AstraZeneca." NGS-based companion diagnostics are increasingly used to match patients with new therapies for cancer and other diseases. More than 90 percent of AstraZeneca's clinical pipeline, across all main areas from oncology, cardiovascular and renal to metabolic and respiratory disease, are targeted precision medicine therapies. "Using the latest diagnostic science allows us to match the best treatment to the patient," said Ruth March, senior vice president, precision medicine and biosamples, AstraZeneca. "This collaboration with Thermo Fisher offers the technology, expertise and ability to decentralize CDx tests to local healthcare providers across our global markets, which will help us identify more patients around the world who may benefit from treatments and effective patient care." Thermo Fisher currently offers the only globally distributable NGS CDx solution approved and reimbursed by government and commercial insurers in more than 15 countries, including the U.S., multiple European nations, Japan, South Korea and the Middle East, and covering more than 550 million lives globally. To expand global access to a growing list of precision medicine therapies, in 2019 Thermo Fisher introduced the Ion Torrent Genexus System*, the first fully-integrated NGS platform featuring an automated specimen-to-report workflow that economically delivers results in a single day. The company's complete NGS workflow, powered by Ion AmpliSeq technology, includes multiple solutions for solid tumor biomarkers and liquid biopsy testing. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Read More

PHARMACY MARKET

Lilly Collaborates with Samsung to boost COVID-19 antibody manufacturing amid supply concerns

Lilly | November 18, 2020

Seven days after Eli Lilly won a FDA crisis approval for its COVID-19 counter acting agent, worries over restricted supplies are as of now springing up, and the organization is getting an accomplished assembling accomplice to help with the worldwide scale-up. Under a drawn out arrangement with Samsung Biologics, the organizations are set to "incredibly quicken the worldwide gracefully" for Lilly's COVID-19 antibodies, Samsung Biologics said in a delivery. Lilly would like to make up to 1 million dosages this year and a lot more in 2021, Reuters reports. The accomplices entered an underlying assembling association back in May, and, from that point forward, Samsung created a first clump of dynamic drug fixing in spite of struggling getting crude materials. The organizations took care of the tech move in under a quarter of a year, a consequence of routine collaborations between specialists at both medication creators, Samsung Biologics said. Lilly's bamlanivimab scored a FDA crisis use approval a week ago in gentle to-direct COVID-19 patients who are at a high danger of advancing to extreme illness. The FDA said the medication isn't approved in hospitalized patients, and Lilly is instructing imbuement inside 10 days concerning manifestation beginning. Before the crisis gesture, the organization entered a flexibly manage the U.S. government for 300,000 dosages at $1,250 per portion. All things considered, the stock could last only multi week dependent on current disease patterns, Reuters reports. While the arrangement incorporates a possibility for additional portions, specialists told the news administration they expect the medications will turn into a business drug sooner or later.

Read More

RESEARCH

Pfizer, Moderna urge calm as they launch tests of vaccines against mutated COVID-19

Pfizer | December 29, 2020

After a changed, quick spreading variation of COVID-19 in the U.K. disturbed worldwide travel throughout the end of the week, an upsetting inquiry arose: Will the new antibodies from Pfizer and Moderna neutralize this startling new strain of the infection? Presently the two organizations, alongside Pfizer's COVID-19 accomplice BioNTech, are racing to quiet an apprehensive public. They're dispatching new investigations intended to demonstrate their mRNA-based shots will fight off the new Covid strain, while at the same time communicating certainty this new antibody innovation is ideal for ensuring against quickly changing infections. Pfizer and BioNTech have tried their antibody "for its capacity to kill various freak strains. Until now, we have discovered steady inclusion of the multitude of strains tried," they said in an assertion. The organizations are currently gathering information from individuals who have gotten the shot to decide how well they "might have the option to kill the new strain from the U.K.," Pfizer added. Moderna didn't promptly react to a solicitation for input yet said in an assertion gave to other news sources that it expects "that the Moderna immunization instigated insusceptibility would be defensive against the variations as of late portrayed in the U.K.," and that it "will play out extra tests in the coming a long time to affirm this desire." Pfizer brought up that when SARS-CoV-2, the infection that causes COVID-19, first arose a year prior, it was clear there was more than one strain of it, and that it was transforming as it spread. SARS-CoV-2 is a RNA infection, and all things considered, it has "astoundingly high [mutation] rates" on the grounds that the chemicals it utilizes for replication are "inclined to mistakes when making new infection duplicates," the organization said. "One reason Pfizer and BioNTech decided to use a mRNA stage is a direct result of the potential for the adaptability of the innovation in contrast with customary immunization advancements," including the capacity to change the RNA arrangement in the antibody, should a strain arise that is not covered by the current shot," Pfizer added.

Read More